The calcimimetic R-568 increases vitamin D receptor expression in rat parathyroid glands - PubMed (original) (raw)

. 2007 May;292(5):F1390-5.

doi: 10.1152/ajprenal.00262.2006. Epub 2007 Jan 2.

Affiliations

• PMID: 17200160
• DOI: 10.1152/ajprenal.00262.2006

Free article

The calcimimetic R-568 increases vitamin D receptor expression in rat parathyroid glands

M E Rodriguez et al. Am J Physiol Renal Physiol. 2007 May.

Free article

Abstract

We previously demonstrated that extracellular calcium regulates vitamin D receptor (VDR) expression by parathyroid cells. Since the calcimimetic R-568 potentiates the effects of calcium on the calcium-sensing receptor, it was hypothesized that administration of R-568 may result in increased VDR expression in parathyroid tissue. In vitro studies of the effect of R-568 on VDR mRNA and protein were conducted in cultures of whole rat parathyroid glands and human hyperplastic parathyroid glands. In vivo studies in Wistar rats examined the effect of R-568 and calcitriol alone and in combination. Incubation of rat parathyroid glands in vitro with R-568 (0.001-1 microM) resulted in a dose-dependent decrease in parathyroid hormone (PTH) secretion and an increase in VDR expression (mean +/- SE). Incubation in 1 mM calcium + 0.001 microM R-568 elicited an increase in VDR mRNA (306 +/- 46%) similar to the maximum increase detected with 1.5 mM calcium (330 +/- 42%). In vivo, VDR mRNA was increased after administration of R-568 (168 +/- 9%, P < 0.001 vs. control) or calcitriol (198 +/- 16%, P < 0.001 vs. control). Treatment with R-568 also increased VDR protein in normal rat parathyroid glands and in human parathyroid glands with diffuse, but not nodular, hyperplasia. In conclusion, the present study shows that the calcimimetic R-568 exerts a stimulatory effect on VDR expression in the parathyroid glands of study models and provides additional evidence for the use of calcimimetics in the treatment of secondary hyperparathyroidism.

PubMed Disclaimer

Similar articles

• The roles of calcium and 1,25-dihydroxyvitamin D3 in the regulation of vitamin D receptor expression by rat parathyroid glands.
  Brown AJ, Zhong M, Finch J, Ritter C, Slatopolsky E. Brown AJ, et al. Endocrinology. 1995 Apr;136(4):1419-25. doi: 10.1210/endo.136.4.7895652. Endocrinology. 1995. PMID: 7895652
• Direct upregulation of parathyroid calcium-sensing receptor and vitamin D receptor by calcimimetics in uremic rats.
  Mendoza FJ, Lopez I, Canalejo R, Almaden Y, Martin D, Aguilera-Tejero E, Rodriguez M. Mendoza FJ, et al. Am J Physiol Renal Physiol. 2009 Mar;296(3):F605-13. doi: 10.1152/ajprenal.90272.2008. Epub 2008 Dec 17. Am J Physiol Renal Physiol. 2009. PMID: 19091789
• Calcimimetics normalize the phosphate-induced stimulation of PTH secretion in vivo and in vitro.
  Almaden Y, Rodriguez-Ortiz ME, Canalejo A, Cañadillas S, Canalejo R, Martin D, Aguilera-Tejero E, Rodríguez M. Almaden Y, et al. J Nephrol. 2009 Mar-Apr;22(2):281-8. J Nephrol. 2009. PMID: 19384847
• Tricking the parathyroid gland with novel calcimimetic agents.
  Nemeth EF, Bennett SA. Nemeth EF, et al. Nephrol Dial Transplant. 1998 Aug;13(8):1923-5. doi: 10.1093/ndt/13.8.1923. Nephrol Dial Transplant. 1998. PMID: 9719139 Review. No abstract available.
• [Calcimimetics, mechanisms of action and therapeutic applications].
  Ureña P, Legoupil N, de Vernejoul MC. Ureña P, et al. Presse Med. 2005 Sep 10;34(15):1095-100. doi: 10.1016/s0755-4982(05)84125-9. Presse Med. 2005. PMID: 16334889 Review. French.

Cited by

• [The role of calcium sensitive and vitamin D receptors in the pathogenesis of sporadic multiple parathyroid gland disease].
  Ilyicheva EA, Shurygina IA, Dremina NN, Bersenev GA, Grigoryev EG. Ilyicheva EA, et al. Probl Endokrinol (Mosk). 2023 Jun 30;69(3):24-34. doi: 10.14341/probl13207. Probl Endokrinol (Mosk). 2023. PMID: 37448244 Free PMC article. Russian.
• Treatment of Hyperparathyroidism (SHPT).
  Hernandes FR, Goldenstein P, Custódio MR. Hernandes FR, et al. J Bras Nefrol. 2021 Dec 3;43(4 Suppl 1):645-649. doi: 10.1590/2175-8239-JBN-2021-S107. eCollection 2021. J Bras Nefrol. 2021. PMID: 34910799 Free PMC article. No abstract available.
• The impact of CASR A990G polymorphism in response to cinacalcet treatment in hemodialysis patients with secondary hyperparathyroidism.
  Ngamkam J, Vadcharavivad S, Areepium N, Auamnoy T, Takkavatakarn K, Katavetin P, Tiranathanagul K, Praditpornsilpa K, Eiam-Ong S, Susantitaphong P. Ngamkam J, et al. Sci Rep. 2021 Sep 9;11(1):18006. doi: 10.1038/s41598-021-97587-8. Sci Rep. 2021. PMID: 34504264 Free PMC article.
• Osteoporosis in Patients with Chronic Kidney Diseases: A Systemic Review.
  Hsu CY, Chen LR, Chen KH. Hsu CY, et al. Int J Mol Sci. 2020 Sep 18;21(18):6846. doi: 10.3390/ijms21186846. Int J Mol Sci. 2020. PMID: 32961953 Free PMC article.
• Case report: Electron microscopic evaluation of bone from a patient treated with cinacalcet hydrochloride, maxacalcitol, and alfacalcidol for hyperparathyroid bone disease with secondary hyperparathyroidism.
  Yajima A, Tsuchiya K, Bonewald LF, Inaba M, Tominaga Y, Tanizawa T, Ito A, Nitta K. Yajima A, et al. Osteoporos Int. 2018 May;29(5):1203-1209. doi: 10.1007/s00198-018-4402-3. Epub 2018 Feb 28. Osteoporos Int. 2018. PMID: 29492624

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon